Patents by Inventor Elizabeth E. Rogers

Elizabeth E. Rogers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11942194
    Abstract: The present disclosure provides systems and methods for assessing a mental state of a subject in a single session or over multiple different sessions, using for example an automated module to present and/or formulate at least one query based in part on one or more target mental states to be assessed. The query may be configured to elicit at least one response from the subject. The query may be transmitted in an audio, visual, and/or textual format to the subject to elicit the response. Data comprising the response from the subject can be received. The data can be processed using one or more individual, joint, or fused models. One or more assessments of the mental state associated with the subject can be generated for the single session, for each of the multiple different sessions, or upon completion of one or more sessions of the multiple different sessions.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: March 26, 2024
    Assignee: Ellipsis Health, Inc.
    Inventors: Elizabeth E. Shriberg, Michael Aratow, Mainul Islam, Amir Hossein Harati Nejad Torbati, Tomasz Rutowski, David Lin, Yang Lu, Farshid Haque, Robert D. Rogers
  • Patent number: 7189891
    Abstract: Novel molecules of the multi-drug and toxin efflux (MATE) family of molecules, designated herein as mutant ferric reductase defective (FRD3) nucleic acid and protein molecules are disclosed. The FRD3 nucleic acid and protein molecules are useful as modulating agents in regulating metal homeostasis, e.g., iron homeostasis. The invention further describes transgenic plants in which expression of a FRD3 polypeptide of the invention is altered. Compositions containing FRD3 molecules and methods of using such molecules are also provided.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: March 13, 2007
    Assignee: The Trustees of Dartmouth College
    Inventors: Mary Lou Guerinot, Elizabeth E. Rogers
  • Publication number: 20040154056
    Abstract: Novel molecules of the multi-drug and toxin efflux (MATE) family of molecules, designated herein as mutant ferric reductase defective (FRD3) nucleic acid and protein molecules are disclosed. The FRD3 nucleic acid and protein molecules are useful as modulating agents in regulating metal homeostasis, e.g., iron homeostasis. The invention further describes transgenic plants in which expression of a FRD3 polypeptide of the invention is altered. Compositions containing FRD3 molecules and methods of using such molecules are also provided.
    Type: Application
    Filed: September 25, 2003
    Publication date: August 5, 2004
    Inventors: Mary Lou Guerinot, Elizabeth E. Rogers